The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2018 | Immunotherapy: will we reach a point where we can curatively treat advanced NSCLC?
With the great promise that immunotherapy holds, there are hopes that it will revolutionize the treatment of lung cancer. Here, Solange Peters, MD, PhD, of Lausanne University Hospital, Lausanne, France, discusses whether, by combining and personalizing immunotherapy, we could reach a point where we can curatively treat advanced non-small cell lung cancer (NSCLC). This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.
